Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL
Cancer Discov. 2014 4 (2): 232-45

PMID: 24356096 · PMCID: PMC3946308 · DOI:10.1158/2159-8290.CD-13-0286

MeSH Terms (17)

Antineoplastic Combined Chemotherapy Protocols Cell Line, Tumor Cluster Analysis DNA Copy Number Variations Drug Resistance, Neoplasm Female Gene Amplification Gene Expression Profiling Genes, myc Humans Ki-67 Antigen Myeloid Cell Leukemia Sequence 1 Protein Neoadjuvant Therapy Neoplasm, Residual Prognosis Treatment Outcome Triple Negative Breast Neoplasms

Connections (10)

This publication is referenced by other Labnodes entities: